42 / 43
CONCLUSIONS
ü
PRRT is a well tolerated and effective treatment in NEN (irrespective of primary tumor site)
ü
PRRT leads to significant improvement of clinical symptoms (QoL)
ü
Somatostatin receptor expression is a strong predictive marker
ü
PRRT: part of guidelines of major scientific and clinical societies
ü
Pending to define the best therapeutic sequence, standardization of protocols, ….
ü
Future perspectives
ü
Combination therapies
ü
Novel targets and radioisotopes
ü
New predictive markers